
Opinion|Videos|July 31, 2024
Patient Case: KRAS G12C Non–Small Cell Lung Cancer
Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.

An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.

The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer
2
FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC
3
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
4
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
5

